Abdoulaye Karaboué

1.6k total citations
45 papers, 1.0k citations indexed

About

Abdoulaye Karaboué is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrine and Autonomic Systems. According to data from OpenAlex, Abdoulaye Karaboué has authored 45 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Endocrine and Autonomic Systems. Recurrent topics in Abdoulaye Karaboué's work include Colorectal Cancer Treatments and Studies (17 papers), Circadian rhythm and melatonin (12 papers) and Cancer Treatment and Pharmacology (12 papers). Abdoulaye Karaboué is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Circadian rhythm and melatonin (12 papers) and Cancer Treatment and Pharmacology (12 papers). Abdoulaye Karaboué collaborates with scholars based in France, United Kingdom and Belgium. Abdoulaye Karaboué's co-authors include Françis Lévi, Pasquale F. Innominato, Sylvie Giacchetti, Mohamed Bouchahda, C. Focan, René Adam, Benoît Baron, Thierry Moreau, F. Kreutz and D Focan-Henrard and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Advanced Drug Delivery Reviews.

In The Last Decade

Abdoulaye Karaboué

44 papers receiving 989 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abdoulaye Karaboué France 19 490 412 269 178 164 45 1.0k
Francis Lévi France 10 383 0.8× 244 0.6× 198 0.7× 104 0.6× 59 0.4× 16 727
Mohamed Bouchahda France 17 230 0.5× 496 1.2× 136 0.5× 169 0.9× 74 0.5× 43 801
F Brivio Italy 22 393 0.8× 435 1.1× 220 0.8× 135 0.8× 34 0.2× 61 1.3k
Vittorio Fossati Italy 12 240 0.5× 233 0.6× 78 0.3× 128 0.7× 32 0.2× 28 659
Sofia Meregalli Italy 16 310 0.6× 213 0.5× 113 0.4× 116 0.7× 42 0.3× 37 821
Massimo Vaghi Italy 19 201 0.4× 393 1.0× 77 0.3× 166 0.9× 21 0.1× 51 1.1k
Huqin Zhang China 12 85 0.2× 85 0.2× 57 0.2× 78 0.4× 37 0.2× 26 548
E. Tisi Italy 16 180 0.4× 212 0.5× 85 0.3× 87 0.5× 13 0.1× 26 589
Sergio Crispino Italy 18 179 0.4× 376 0.9× 97 0.4× 225 1.3× 22 0.1× 61 1.1k
Sarah Song Australia 16 46 0.1× 315 0.8× 49 0.2× 153 0.9× 82 0.5× 22 926

Countries citing papers authored by Abdoulaye Karaboué

Since Specialization
Citations

This map shows the geographic impact of Abdoulaye Karaboué's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdoulaye Karaboué with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdoulaye Karaboué more than expected).

Fields of papers citing papers by Abdoulaye Karaboué

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abdoulaye Karaboué. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdoulaye Karaboué. The network helps show where Abdoulaye Karaboué may publish in the future.

Co-authorship network of co-authors of Abdoulaye Karaboué

This figure shows the co-authorship network connecting the top 25 collaborators of Abdoulaye Karaboué. A scholar is included among the top collaborators of Abdoulaye Karaboué based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdoulaye Karaboué. Abdoulaye Karaboué is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Landré, Thierry, Abdoulaye Karaboué, Zachary S. Buchwald, et al.. (2024). Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 9(2). 102220–102220. 32 indexed citations
2.
Karaboué, Abdoulaye, et al.. (2024). Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?. British Journal of Cancer. 131(5). 783–796. 23 indexed citations
3.
Innominato, Pasquale F., Sandra Komarzynski, Robert Dallmann, et al.. (2021). Impact of assessment frequency of patient-reported outcomes: an observational study using an eHealth platform in cancer patients. Supportive Care in Cancer. 29(11). 6167–6170. 9 indexed citations
4.
Bouchahda, Mohamed, Raphaël Saffroy, Abdoulaye Karaboué, et al.. (2020). UndetectableRAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients WithRAS-Mutant Metastatic Colorectal Cancer. JCO Precision Oncology. 4(4). 1070–1079. 22 indexed citations
5.
Ulusakarya, Ayhan, Abdoulaye Karaboué, Oriana Ciacio, et al.. (2020). A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer. 20(1). 515–515. 11 indexed citations
6.
Ulusakarya, Ayhan, et al.. (2018). Patient-tailored FOLFIRINOX in the first-line treatment of patients (pts) with advanced pancreatic cancer (PC).. Journal of Clinical Oncology. 36(4_suppl). 499–499. 1 indexed citations
7.
8.
Lévi, Françis, Abdoulaye Karaboué, Raphaël Saffroy, et al.. (2017). Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British Journal of Cancer. 117(7). 965–973. 16 indexed citations
9.
Innominato, Pasquale F., Sandra Komarzynski, Ali Mohammad‐Djafari, et al.. (2016). Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project. Journal of Medical Internet Research. 18(11). e305–e305. 23 indexed citations
10.
Lévi, Francis, Abdoulaye Karaboué, Marie-Christine Étienne-Grimaldi, et al.. (2016). Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. Clinical Pharmacokinetics. 56(2). 165–177. 23 indexed citations
11.
12.
Ortiz‐Tudela, Elisabet, Ida Iurisci, J Le Beau, et al.. (2013). The circadian rest‐activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. International Journal of Cancer. 134(11). 2717–2725. 50 indexed citations
13.
Innominato, Pasquale F., Sylvie Giacchetti, Thierry Moreau, et al.. (2013). Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 119(14). 2564–2573. 40 indexed citations
14.
Lévi, Françis, Arti Parganiha, Abdoulaye Karaboué, et al.. (2012). Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(4_suppl). 464–464. 7 indexed citations
15.
Innominato, Pasquale F., Sylvie Giacchetti, C. Focan, et al.. (2011). Chemotherapy-induced neutropenia (neutro) association with survival in metastatic colorectal cancer (MCC): Schedule dependency.. Journal of Clinical Oncology. 29(15_suppl). e13024–e13024. 1 indexed citations
16.
Innominato, Pasquale F., Sylvie Giacchetti, Thierry Moreau, et al.. (2011). Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin–5-Fluorouracil–Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963). Chronobiology International. 28(7). 586–600. 36 indexed citations
17.
Bouchahda, Mohamed, Abdoulaye Karaboué, Raphaël Saffroy, et al.. (2010). Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemotherapy and Pharmacology. 66(3). 605–609. 52 indexed citations
18.
Lévi, Françis, Abdoulaye Karaboué, Lee Gorden, et al.. (2010). Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemotherapy and Pharmacology. 67(2). 339–348. 42 indexed citations
19.
Bouchahda, Mohamed, Teresa Macarulla, Jean‐Baptiste Bachet, et al.. (2008). Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Critical Reviews in Oncology/Hematology. 67(3). 255–262. 41 indexed citations
20.
Lévi, Françis, C. Focan, Abdoulaye Karaboué, et al.. (2007). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery Reviews. 59(9-10). 1015–1035. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francis Lévi Breakdown of academic impact, for papers by Mohamed Bouchahda Breakdown of academic impact, for papers by F Brivio Breakdown of academic impact, for papers by Vittorio Fossati Breakdown of academic impact, for papers by Sofia Meregalli Breakdown of academic impact, for papers by Massimo Vaghi Breakdown of academic impact, for papers by Huqin Zhang Breakdown of academic impact, for papers by E. Tisi Breakdown of academic impact, for papers by Sergio Crispino Breakdown of academic impact, for papers by Sarah Song
Rankless by CCL
2026